lilly compound tirzepatide Eli finds impurity in compounded Compound Tirzepatide

With the ongoing obesity epidemic 1,2 and the emergence of promising new pharmacologic agents for obesity such as GLP-1 agonists, 3 providers may be increasingly called upon to consider incorporating weight-loss pharmacotherapy into clinical practice

PlexusDx recommends discussing your specific metabolic profile with your provider to determine which compound aligns best with your goals

The novel peptide is biased towards GLP-1R agonism versus GCGR with a 3-4 fold reduced potency at the GLP-1R compared to native GLP-1 and around an 8-fold reduced potency at the GCGR compared to native glucagon

A two-tailed students t-test was performed for statistical analysis